Vaxart, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vaxart, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $237.26M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $28.70M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $7.38M | Mar 20, 2025 |
| FY2018 | Dec 31, 2018 | $1.77M | Feb 6, 2019 |
| FY2018 | Sep 30, 2018 | $281.0K | Feb 6, 2019 |
| FY2018 | Jun 30, 2018 | $608.0K | Feb 6, 2019 |
| FY2018 | Mar 31, 2018 | $1.50M | Feb 6, 2019 |
| FY2018 | Dec 31, 2017 | $760.0K | Feb 6, 2019 |
| FY2018 | Sep 30, 2017 | $915.0K | Feb 6, 2019 |
| FY2018 | Jun 30, 2017 | $1.85M | Feb 6, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.33M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($66.95M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($82.47M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($107.76M) | Mar 14, 2024 |
| FY2021 | Dec 31, 2021 | ($20.76M) | Feb 24, 2022 |
| FY2021 | Sep 30, 2021 | ($17.58M) | Feb 24, 2022 |
| FY2021 | Jun 30, 2021 | ($16.12M) | Feb 24, 2022 |
| FY2021 | Mar 31, 2021 | ($16.01M) | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | ($13.86M) | Feb 24, 2022 |
| FY2021 | Sep 30, 2020 | ($8.09M) | Feb 24, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.07M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($66.29M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($83.35M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($114.59M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($72.75M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($30.17M) | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | ($15.79M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($21.76M) | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | ($10.02M) | Feb 6, 2019 |
| FY2017 | Jun 30, 2017 | ($27.50M) | Sep 1, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $201.58M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $74.21M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $68.14M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $81.05M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $48.75M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $19.86M | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | $14.54M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $17.28M | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | $12.36M | Feb 6, 2019 |
| FY2017 | Jun 30, 2017 | $28.30M | Sep 1, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.71M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($44.76M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($70.45M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($94.78M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($59.83M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($23.75M) | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | ($13.09M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($14.55M) | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | ($10.04M) | Feb 6, 2019 |
| FY2015 | Jun 30, 2015 | ($9.60M) | Sep 11, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $145.0K | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $554.0K | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.87M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $9.60M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $5.16M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.22M | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | $850.0K | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $707.0K | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | $117.0K | Feb 6, 2019 |
| FY2017 | Jun 30, 2016 | $200.0K | Sep 1, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $186.08M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $166.39M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $91.83M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $153.85M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $221.17M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $152.58M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $37.03M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $35.23M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $4.52M | Feb 6, 2019 |
| FY2017 | Jun 30, 2017 | $40.10M | Sep 1, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.28M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $107.46M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $34.03M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $43.25M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $33.64M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $29.18M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $24.08M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $23.99M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $43.25M | Feb 6, 2019 |
| FY2017 | Jun 30, 2017 | $21.40M | Sep 1, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $87.80M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $58.93M | Mar 13, 2026 |
| FY2025 | Dec 31, 2023 | $57.81M | Mar 13, 2026 |
| FY2024 | Dec 31, 2022 | $110.60M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $187.53M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $123.40M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $12.95M | Feb 24, 2022 |
| FY2021 | Dec 31, 2018 | $11.21M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | ($38.72M) | Feb 25, 2021 |
| FY2017 | Jun 30, 2017 | $18.70M | Sep 1, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.51M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | $4.51M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | $4.51M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $4.51M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $4.51M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Feb 24, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($460.20M) | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | ($476.52M) | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | ($409.57M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($327.11M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($219.35M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($148.88M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($116.66M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($97.99M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($79.98M) | Feb 6, 2019 |
| FY2017 | Jun 30, 2017 | ($163.80M) | Sep 1, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $34.76M | Mar 14, 2024 |
| FY2023 | Dec 31, 2022 | $44.01M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $143.75M | Mar 15, 2023 |
| FY2018 | Dec 31, 2018 | $11.51M | Feb 6, 2019 |
| FY2018 | Dec 31, 2017 | $1.57M | Feb 6, 2019 |
| FY2017 | Jun 30, 2017 | $17.70M | Sep 1, 2017 |
| FY2018 | Dec 31, 2016 | $8.41M | Feb 6, 2019 |
| FY2017 | Jun 30, 2016 | $49.70M | Sep 1, 2017 |
| FY2017 | Jun 30, 2015 | $44.70M | Sep 1, 2017 |
| FY2016 | Jun 30, 2014 | $81.70M | Sep 13, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $17.74M | Feb 6, 2019 |
| FY2018 | Dec 31, 2017 | $15.90M | Feb 6, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 15, 2023 |
| FY2020 | Dec 31, 2018 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2018 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2018 | (1) | Feb 25, 2021 |
| FY2020 | Mar 31, 2018 | 0 | Feb 25, 2021 |
| FY2017 | Jun 30, 2017 | 0 | Sep 1, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 13, 2026 |
| FY2020 | Dec 31, 2018 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2018 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2018 | (1) | Feb 25, 2021 |
| FY2020 | Mar 31, 2018 | 0 | Feb 25, 2021 |
| FY2017 | Jun 30, 2017 | 0 | Sep 1, 2017 |
| FY2016 | Jun 30, 2016 | 0 | Sep 13, 2016 |
| FY2016 | Mar 31, 2016 | 0 | Sep 13, 2016 |
| FY2016 | Dec 31, 2015 | 0 | Sep 13, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 240.49M | Mar 13, 2026 |
| FY2025 | Dec 31, 2024 | 227.77M | Mar 13, 2026 |
| FY2024 | Dec 31, 2023 | 153.45M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 134.20M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 125.59M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 110.27M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 48.25M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 7.14M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | 138,492 | Feb 6, 2019 |
| FY2017 | Jun 30, 2017 | 38.65M | Sep 1, 2017 |